ImmunityBio Inc (NASDAQ:IBRX) shares, rose in value on Wednesday, June 18, without any change to the previous day’s close as strong demand from buyers drove the stock to $2.84.
Actively observing the price movement in the last trading, the stock closed the session at $2.84, falling within a range of $2.83 and $2.96. The value of beta (5-year monthly) was -0.065. Referring to stock’s 52-week performance, its high was $7.63, and the low was $1.83. On the whole, IBRX has fluctuated by 1.43% over the past month.
With the market capitalization of ImmunityBio Inc currently standing at about $2.51 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-12.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that IBRX’s technical picture suggests that short-term indicators denote the stock is a 25% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of IBRX currently trading nearly -1.32% and 6.87% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 49.23, while the 7-day volatility ratio is showing 5.14% which for the 30-day chart, stands at 5.14%. Furthermore, ImmunityBio Inc (IBRX)’s beta value is -0.01, and its average true range (ATR) is 0.25.
A comparison of ImmunityBio Inc (IBRX) with its peers suggests the former has fared considerably weaker in the market. IBRX showed an intraday change of 0.00% in last session, and over the past year, it shrunk by -52.35%%.
Data on historical trading for ImmunityBio Inc (NASDAQ:IBRX) indicates that the trading volumes over the past 10 days have averaged 12.49 and over the past 3 months, they’ve averaged 9.19 million. According to company’s latest data on outstanding shares, there are 853.39 million shares outstanding.
Nearly 89.60% of ImmunityBio Inc’s shares belong to company insiders and institutional investors own 9.08% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 72.12 million shares as on 2025-05-30, resulting in a short ratio of 6.8. According to the data, the short interest in ImmunityBio Inc (IBRX) stood at 3157.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 68.76 million. The stock has risen by 10.94% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the IBRX stock heading into the next quarter.
